Treatment Effectiveness
User reported effectiveness ratings Low-Dose Naltrexone (LDN) for various conditions.
| Conditions | Major Improvement | Moderate Improvement | Much Worse | No Effect | Worse | Responses |
|---|---|---|---|---|---|---|
| Aging | 47% | 24% | 6% | 24% | 0% | 17 |
| Allergic Rhinitis (Hay Fever) | 20% | 20% | 20% | 40% | 0% | 5 |
| Arthritis | 56% | 25% | 6% | 13% | 0% | 16 |
| Asthma | 40% | 20% | 20% | 20% | 0% | 5 |
| Chronic Cerebrospinal Venous Insufficiency (CCSVI) | 14% | 14% | 14% | 43% | 14% | 7 |
| Chronic Fatigue Syndrome | 33% | 29% | 9% | 27% | 3% | 79 |
| Chronic Pain Syndrome | 50% | 50% | 0% | 0% | 0% | 4 |
| Common Cold | 67% | 33% | 0% | 0% | 0% | 3 |
| Endometriosis | 25% | 0% | 0% | 75% | 0% | 4 |
| Fibromyalgia | 54% | 19% | 4% | 23% | 0% | 57 |
| Hypothyroidism | 17% | 42% | 0% | 33% | 8% | 12 |
| Irritable Bowel Syndrome | 33% | 17% | 11% | 33% | 6% | 18 |
| Mitral Valve Prolapse | 0% | 20% | 40% | 40% | 0% | 5 |
| Restless Legs Syndrome | 33% | 0% | 0% | 67% | 0% | 3 |
Outcomes
Below is the degree of change seen after Low-Dose Naltrexone (LDN) is higher than average.
|
|
Don't see what you're looking for?
Create a study and help us eradicate suffering!
Outcomes Label
Low-Dose Naltrexone (LDN) Info
| Property | Value |
|---|---|
| Variable Name | Low-Dose Naltrexone (LDN) |
| Aggregation Method | SUM |
| Analysis Performed At | 2020-03-26 |
| Duration of Action | 21 days |
| Filling Value | 0 |
| Minimum Allowed Value | 0 count |
| Number of Aggregate Predictors | 0 |
| Number of Aggregate Outcomes | 0 |
| Number of Measurements | 0 |
| Number of Measurements (including those generated by tagged, joined, or child variables) | 0 |
| Public | true |
| Onset Delay | 30 minutes |
| Unit | Count |
| User Variables | 0 |
| Variable Category | Treatments |
| Variable ID | 94259 |